Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a detailed safety analysis of the randomized OptiTROP-Breast01 study.

In 30 seconds

This randomized controlled trial analyzed the safety profile of sacituzumab tirumotecan (sac-TMT) in 262 patients with previously treated metastatic triple-negative breast cancer. The study found that most patients with grade 3 or higher adverse events recovered to grade 2 or lower within 14 days, indicating a manageable safety profile for sac-TMT.

Key findings

• Most patients with grade 3 or higher key adverse events recovered to grade 2 or lower within 14 days.
• The incidence of treatment-related adverse events decreased over time among patients with treatment duration over 7 months.
• Median time to onset of grade 3 or higher key adverse events primarily occurred within the first two cycles.

Why it matters

Understanding the safety profile of sac-TMT is crucial for clinicians managing metastatic triple-negative breast cancer, as it informs treatment decisions and patient management strategies, particularly regarding adverse event monitoring and supportive care.